NASDAQ: RAREUltragenyx Pharmaceutical Inc Earnings Dates, Reports, Calls
Ultragenyx Pharmaceutical earnings were -$586.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest RARE earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$92.0M, down 50.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RARE reported annual earnings of -$575.0M, with 1.1% growth.
RARE earnings history
Current Revenue
$717.2M
Current Earnings
-$586.0M
Current Profit Margin
-81.7%
RARE Return on Equity
Current Company
N/A
Current Industry
-6.9%
Current Market
29.1%
RARE Return on Assets
Current Company
-44.4%
Current Industry
-7%
RARE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance
Be the first to know when RARE announces earnings.
RARE Return on Capital Employed
Current Company
-63.77%
Current Industry
-1.4%
RARE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance
RARE vs Biotech Stocks
Ultragenyx Pharmaceutical Earnings Reports & History FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.